Skip to search formSkip to main contentSkip to account menu

5-hydroxymethyl tolterodine

National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

Benzhydryl CompoundsCresols

Narrower (1)

PNU 200577

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Design of hydrogels of 5‐hydroxymethyl tolterodine and their studies on pharmacokinetics, pharmacodynamics and transdermal mechanism
Review
2013
Review
2013
Rationale for the Use of Anticholinergic Agents in Overactive Bladder With Regard to Central Nervous System and Cardiovascular System Side Effects
Purpose Central nervous system (CNS) and cardiovascular system (CVS) side effects of anticholinergic agents used to treat… 
Highly Cited
2011
Highly Cited
2011
A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder.
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT This study provides antimuscarinic agents for overactive bladder (OAB) display variable… 
2011
2011
Comparison of pharmacokinetic variability of fesoterodine vs. tolterodine extended release in cytochrome P450 2D6 extensive and poor metabolizers.
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT Tolterodine and 5-hydroxymethyl tolterodine (5-HMT) are equipotent active moieties of… 
2011
2011
Fesoterodine: Individualised Treatment of Urgency Urinary Incontinence Across Patient Groups
2011
2011
Effects of the moderate CYP3A4 inhibitor, fluconazole, on the pharmacokinetics of fesoterodine in healthy subjects.
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT Available data suggest that fesoterodine dosage should not exceed 4 mg once daily when… 
Review
2009
Review
2009
The design and development of fesoterodine as a prodrug of 5-hydroxymethyl tolterodine (5-HMT), the active metabolite of tolterodine.
This review highlights the design and development of fesoterodine (Toviaz) as a prodrug of 5-hydroxymethyl tolterodine (5-HMT… 
2009
2009
Urodynamic evaluation of fesoterodine metabolite, doxazosin and their combination in a rat model of partial urethral obstruction
To evaluate the urodynamic effects of fesoterodine, a new antimuscarinic agent, alone and combined with doxazosin, in a rat model… 
2009
2009
The pharmacokinetic profile of fesoterodine: similarities and differences to tolterodine.
BACKGROUND Fesoterodine is a new antimuscarinic agent developed for the treatment of overactive bladder. Fesoterodine itself is… 
Highly Cited
2008
Highly Cited
2008
Pharmacokinetic profile of fesoterodine.
OBJECTIVE Fesoterodine is a new antimuscarinic agent for the treatment of overactive bladder. Following oral administration… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)